Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

1.800 -0.230 (-11.33%)
Streaming Delayed Price Updated: 12:30 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 276,929
Open 1.990
Bid (Size) 1.800 (10)
Ask (Size) 1.810 (16)
Prev. Close 2.030
Today's Range 1.770 - 1.990
52wk Range 2.020 - 11.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The trading volume of these stocks is deviating from the norm in today's session.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
From Acrivon Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
-68.4%
-68.4%
1 Month
-65.0%
-65.0%
3 Month
-66.7%
-66.7%
6 Month
-74.3%
-74.3%
1 Year
-75.2%
-75.2%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings
Via Benzinga
Exposures Fossil Fuels
Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion
Via Benzinga
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
From Acrivon Therapeutics, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Acrivon Therapeutics, Inc. - Common Stock publicly traded?
Yes, Acrivon Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Acrivon Therapeutics, Inc. - Common Stock trade on?
Acrivon Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acrivon Therapeutics, Inc. - Common Stock?
The ticker symbol for Acrivon Therapeutics, Inc. - Common Stock is ACRV on the Nasdaq Stock Market
What is the current price of Acrivon Therapeutics, Inc. - Common Stock?
The current price of Acrivon Therapeutics, Inc. - Common Stock is 1.800
When was Acrivon Therapeutics, Inc. - Common Stock last traded?
The last trade of Acrivon Therapeutics, Inc. - Common Stock was at 04/01/25 12:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.